Rajat Dhar1, Chad Washington2, Michael Diringer3,2, Allyson Zazulia3,4, Hussain Jafri4, Colin Derdeyn3,2,4, Gregory Zipfel3,2. 1. Division of Neurocritical Care, Department of Neurology, Washington University in St. Louis, 660 S Euclid Avenue, St. Louis, MO, 63110, USA. dharr@neuro.wustl.edu. 2. Department of Neurosurgery, Washington University in St. Louis, St. Louis, MO, 63110, USA. 3. Division of Neurocritical Care, Department of Neurology, Washington University in St. Louis, 660 S Euclid Avenue, St. Louis, MO, 63110, USA. 4. Department of Radiology, Washington University in St. Louis, St. Louis, MO, 63110, USA.
Abstract
BACKGROUND: The phosphodiesterase-5 inhibitor sildenafil has been shown to attenuate delayed cerebral ischemia (DCI) and improve neurologic function in experimental subarachnoid hemorrhage (SAH). We recently demonstrated that it could improve cerebral vasospasm (CVS) in humans after SAH. However, successful therapies for DCI must also restore cerebral blood flow (CBF) and/or autoregulatory capacity. In this study, we tested the effects of sildenafil on CBF in SAH patients at-risk for DCI. METHODS: Six subjects with angiographically confirmed CVS received 30-mg of intravenous sildenafil (mean 9 ± 2 days after aneurysmal SAH). Each underwent (15)O-PET imaging to measure global and regional CBF at baseline and post-sildenafil. RESULTS: Mean arterial pressure declined by 10 mm Hg on average post-sildenafil (8 %, p = 0.01), while ICP was unchanged. There was no change in global CBF (mean 34.5 ± 7 ml/100g/min at baseline vs. 33.9 ± 8.0 ml/100g/min post-sildenafil, p = 0.84). The proportion of brain regions with low CBF (<25 ml/100g/min) was also unchanged after sildenafil infusion. CONCLUSIONS: Infusion of sildenafil does not lead to a change in global or regional perfusion despite a significant reduction in cerebral perfusion pressure. While this could reflect the ineffectiveness of sildenafil-induced proximal vasodilatation to alter brain perfusion, it also suggests that cerebral autoregulatory function was preserved in this group. Future studies should assess whether sildenafil can restore or enhance autoregulation after SAH.
BACKGROUND: The phosphodiesterase-5 inhibitor sildenafil has been shown to attenuate delayed cerebral ischemia (DCI) and improve neurologic function in experimental subarachnoid hemorrhage (SAH). We recently demonstrated that it could improve cerebral vasospasm (CVS) in humans after SAH. However, successful therapies for DCI must also restore cerebral blood flow (CBF) and/or autoregulatory capacity. In this study, we tested the effects of sildenafil on CBF in SAHpatients at-risk for DCI. METHODS: Six subjects with angiographically confirmed CVS received 30-mg of intravenous sildenafil (mean 9 ± 2 days after aneurysmalSAH). Each underwent (15)O-PET imaging to measure global and regional CBF at baseline and post-sildenafil. RESULTS: Mean arterial pressure declined by 10 mm Hg on average post-sildenafil (8 %, p = 0.01), while ICP was unchanged. There was no change in global CBF (mean 34.5 ± 7 ml/100g/min at baseline vs. 33.9 ± 8.0 ml/100g/min post-sildenafil, p = 0.84). The proportion of brain regions with low CBF (<25 ml/100g/min) was also unchanged after sildenafil infusion. CONCLUSIONS: Infusion of sildenafil does not lead to a change in global or regional perfusion despite a significant reduction in cerebral perfusion pressure. While this could reflect the ineffectiveness of sildenafil-induced proximal vasodilatation to alter brain perfusion, it also suggests that cerebral autoregulatory function was preserved in this group. Future studies should assess whether sildenafil can restore or enhance autoregulation after SAH.
Authors: Chad W Washington; Colin P Derdeyn; Rajat Dhar; Eric J Arias; Michael R Chicoine; DeWitte T Cross; Ralph G Dacey; Byung Hee Han; Christopher J Moran; Keith M Rich; Ananth K Vellimana; Gregory J Zipfel Journal: J Neurosurg Date: 2015-08-28 Impact factor: 5.115
Authors: M Diomedi; F Sallustio; B Rizzato; F Ferrante; G Leone; E Spera; M Scarfini; G Bernardi Journal: Neurology Date: 2005-07-28 Impact factor: 9.910
Authors: B Rosengarten; R T Schermuly; R Voswinckel; M G Kohstall; H Olschewski; N Weissmann; W Seeger; M Kaps; F Grimminger; H A Ghofrani Journal: Cerebrovasc Dis Date: 2005-12-23 Impact factor: 2.762
Authors: Rajat Dhar; Michael T Scalfani; Spiros Blackburn; Allyson R Zazulia; Tom Videen; Michael Diringer Journal: Stroke Date: 2012-04-05 Impact factor: 7.914
Authors: Guang Ren; Patrick Tae Joon Hwang; Reid Millican; Juhee Shin; Brigitta C Brott; Thomas van Groen; Craig M Powell; Sushant Bhatnagar; Martin E Young; Ho-Wook Jun; Jeong-A Kim Journal: ACS Appl Mater Interfaces Date: 2022-04-25 Impact factor: 10.383
Authors: Mendel Castle-Kirszbaum; Leon Lai; Julian Maingard; Hamed Asadi; R Andrew Danks; Tony Goldschlager; Ronil V Chandra Journal: Neurosurg Rev Date: 2021-03-08 Impact factor: 3.042
Authors: Mathilde Mh Pauls; Barry Moynihan; Thomas R Barrick; Christina Kruuse; Jeremy B Madigan; Atticus H Hainsworth; Jeremy D Isaacs Journal: J Cereb Blood Flow Metab Date: 2017-12-19 Impact factor: 6.200
Authors: Huichun Xu; Boryana Stamova; Bradley P Ander; Ben Waldau; Glen C Jickling; Frank R Sharp; Nerissa U Ko Journal: Neurocrit Care Date: 2020-08 Impact factor: 3.210